Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential

摘要

Since the first experiences with genetically modified Tcells in the 1980s, the concept of adoptive T cell immunotherapy has been evolved extensively [1, 2]. The introduction of chimeric antigen receptor (CAR), an artificiallydesigned receptor on T cells against desired tumor antigens, has propelled the adoptive T cell therapy toward fairoutcomes. A CAR is usually consisted up of an extracellular single chain fragment of variable (scFv) obtained froman antibody, a hinge, a transmembrane region and intracellular signaling domains [3]. This chimeric receptor provides the possibility for T cells to be activated MHC independently [4]. Therefore, can overcome the MHC downregulation and diminished antigen presentation obserevedin several malignancies [5]. The majority of CAR-T celltrials have been conducted on B cell and T cell malignancyplatforms. Especially, anti-CD19 redirected CAR-T cellscaused great success rate which was complete remissionof 69–90% of patients with pediatric acute lymphoblasticlymphoma [6–10]. Developing generations and multireceptor approaches of CAR-T cells are all planned to maximize the efficacy and decline the side effects [11].